Novozymes estimates that it accounts for 47% of the overall enzymes market. The company spends 14% of its turnover on R&D. The Board of Directors of Novozymes appointed Peder Holk Nielsen as President and CEO with effect from April 1, 2013. Nielsen has vowed to bring more innovation to the market faster.
